SCHEMBL4746366

SCHEMBL4746366

c1ccc(-c2ccc3c(c2)c(-c2ccc(-c4cc5c6ccc(-c7ccccc7)c7c6c(cc5c5ccc(-c6ccccc6)cc45)-c4ncccc4-7)c4ccccc24)cc2c4ccc(-c5ccccc5)c5c4c(cc32)-c2ncccc2-5)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 1/20 0.35
ALK Q9UM73 2/20 0.34
PTGS1 P23219 1/20 0.34
PTGS2 P35354 1/20 0.34
FEN1 P39748 1/20 0.34
TOP2A P11388 1/20 0.33
HTT P42858 2/20 0.32
ALDH1A1 P00352 1/20 0.32
HSD17B10 Q99714 1/20 0.32
IMPDH2 P12268 1/20 0.32
MAPKAPK2 P49137 2/20 0.31
MKNK1 Q9BUB5 1/20 0.31
CTSL P07711 1/20 0.31
PTPRC P08575 1/20 0.31
CTSS P25774 1/20 0.31
PTPN13 Q12923 1/20 0.31
TOP1 P11387 1/20 0.30
CKS1B P61024 1/20 0.30
GLO1 Q04760 1/20 0.30
SKP2 Q13309 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4746378 0.99 PIK3CA (0.34) PIK3CAALKPTGS1PTGS2FEN1
SCHEMBL4746468 0.95 PIK3CA (0.34) PIK3CAALKPTGS1PTGS2FEN1
SCHEMBL4746316 0.95 PIK3CA (0.36) PIK3CAALKPTGS1PTGS2FEN1
SCHEMBL4746334 0.95 PIK3CA (0.36) PIK3CAALKPTGS1PTGS2FEN1
SCHEMBL4745874 0.94 PIK3CA (0.32) PIK3CAALKPTGS1PTGS2FEN1
SCHEMBL4746003 0.94 PIK3CA (0.34) PIK3CAALKPTGS1PTGS2FEN1
SCHEMBL4746453 0.94 PIK3CA (0.34) PIK3CAALKPTGS1PTGS2FEN1
SCHEMBL4745996 0.93 L3MBTL1 (0.33) PIK3CAALKPTGS1PTGS2FEN1
SCHEMBL4746325 0.92 FEN1 (0.35) PIK3CAALKPTGS1PTGS2FEN1
SCHEMBL4746330 0.92 FEN1 (0.35) PIK3CAALKPTGS1PTGS2FEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE NR2E3, OR51E2, AZI2 PIK3CA 3434/4885ALK 312/4885PTGS1 2683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.